rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Context Therapeutics Inc.

CNTX · Nasdaq

Health CareBiotechnologyNot moving yet

CNTX stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 20 weeks. It is 80.8% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 20
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
76 (+21)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$103KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders76+21 on the quarter
New · exited35 · 14
Reported value$34.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Nextech Invest Ltd.unchanged · filed 14 Aug 20267,419,355$4.1M00.0%
Deep Track Capital, LPunchanged · filed 14 Aug 20267,419,355$4.1M00.0%
Soleus Capital Management, L.P.added · filed 11 Aug 20267,063,141$3.9M+100,000+1.4%
BlackRock, Inc.added · filed 7 Aug 20266,169,250$3.4M+5,322,554+628.6%
Avidity Partners Management LPunchanged · filed 14 Aug 20264,998,267$2.8M00.0%
FRANKLIN RESOURCES INCunchanged · filed 13 Aug 20263,803,338$2.1M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,432,052$1.9M+990.0%
Octagon Capital Advisors LPreduced · filed 14 Aug 20263,050,000$1.7M-2,200,000−41.9%
Blue Owl Capital Holdings LPreduced · filed 11 Aug 20262,934,015$1.6M-2,155,000−42.3%
TCG Crossover Management, LLCunchanged · filed 14 Aug 20262,682,696$1.5M00.0%
31 Mar 2023 – 30 Jun 2026
194774Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Andy Pasternak Company insiderDirector · last 24 Jun 20260 · 0
Jennifer Evans Stacey Company insiderDirector · last 24 Jun 20260 · 0
Karen L. Smith Company insiderDirector · last 24 Jun 20260 · 0
Linda West Company insiderDirector · last 24 Jun 20260 · 0
Luke Nathaniel Walker Company insiderDirector · last 24 Jun 20260 · 0
Philip W. Kantoff Company insiderDirector · last 24 Jun 20260 · 0
Alex C. Levit Company insiderChief Legal Officer, Corp. Sec · last 19 Feb 20263 · 0
Jennifer Lynn Minai-Azary Company insiderChief Financial Officer · last 19 Feb 20263 · 0
Karen Deborah Chagin Company insiderChief Medical Officer · last 19 Feb 20260 · 0
Martin A. Lehr Company insiderChief Executive Officer · last 19 Feb 202612 · 0
Ullmann Claudio Dansky Company insiderChief Medical Officer · last 13 Feb 20250 · 0
Richard J. Berman Company insiderDirector · last 13 Jun 20240 · 0

Same industry

MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
XNCR XencorLeading+44%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-65.7%
Share count trendFY 2025 · to 19 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$66.0M
Free cash flowFY 2025 · to 31 Dec 2025−$26.4M

Analyst forecasts

No analyst forecasts yet.